Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.

Gamez, Josep; Gamez, Alejandro; Carmona, Francesc

Gamez, Josep; Gamez, Alejandro; Carmona, Francesc.

Afiliação

Gamez J; Neurology Department, GMA Clinic, European Reference Network on Rare Neuromuscular Diseases, Autonomous University of Barcelona, Barcelona, Spain.
Gamez A; Neurophtalmology Department, Hospital San Rafael, Barcelona, Spain.
Carmona F; Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain.

Muscle Nerve ; 66(5): 612-617, 2022 11.

Article em En | MEDLINE | ID: mdl-36029224

Assuntos

Vacinas contra COVID-19; COVID-19; Miastenia Gravis; Vacinas; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; COVID-19/prevenção & controle; Vacinas contra COVID-19/efeitos adversos; Imunossupressores/uso terapêutico; Miastenia Gravis/tratamento farmacológico; RNA Mensageiro; SARS-CoV-2; Vacinas/uso terapêutico

Palavras-chave

COVID-18; adverse events; exacerbation; mRNA vaccine; myasthenia gravis; reactogenicity; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google